Skip Nav Destination
Issues
1 July 2008
-
Cover Image
Cover Image
The structure of NVP-BEZ235 alone (top) or docked in the catalytic site of PI3Kα (bottom). The model was generated using the coordinates of known PI3Kγ crystal structures. All possible orientations were considered to determine which one was the most consistent with the available structure-activity relationship, in particular with regard to the importance of the hydrogen bond acceptor nitrogen atoms present in the chemical structure of the inhibitor for high potency. For details, see Maira et al., in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Research Articles: Therapeutics, Targets, and Development
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira; Frédéric Stauffer; Josef Brueggen; Pascal Furet; Christian Schnell; Christine Fritsch; Saskia Brachmann; Patrick Chène; Alain De Pover; Kevin Schoemaker; Doriano Fabbro; Daniela Gabriel; Marjo Simonen; Leon Murphy; Peter Finan; William Sellers; Carlos García-Echeverría
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Andrea J. Gonzales; Kenneth E. Hook; Irene W. Althaus; Paul A. Ellis; Erin Trachet; Amy M. Delaney; Patricia J. Harvey; Teresa A. Ellis; Danielle M. Amato; James M. Nelson; David W. Fry; Tong Zhu; Cho-Ming Loi; Stephen A. Fakhoury; Kevin M. Schlosser; Karen E. Sexton; R. Thomas Winters; Jessica E. Reed; Alex J. Bridges; Daniel J. Lettiere; Deborah A. Baker; Jianxin Yang; Helen T. Lee; Haile Tecle; Patrick W. Vincent
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis
Laura P. Stabile; Mary E. Rothstein; Phouthone Keohavong; Jide Jin; Jinling Yin; Stephanie R. Land; Sanja Dacic; The Minh Luong; K. Jin Kim; Austin M. Dulak; Jill M. Siegfried
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Akihiko Miyanaga; Akihiko Gemma; Rintaro Noro; Kiyoko Kataoka; Kuniko Matsuda; Michiya Nara; Tetsuya Okano; Masahiro Seike; Akinobu Yoshimura; Akiko Kawakami; Haruka Uesaka; Hiroki Nakae; Shoji Kudoh
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1α and -2α
Maura Puppo; Florinda Battaglia; Catherine Ottaviano; Silvana Delfino; Domenico Ribatti; Luigi Varesio; Maria Carla Bosco
Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968
Claudio Pisano; Michelandrea De Cesare; Giovanni Luca Beretta; Valentina Zuco; Graziella Pratesi; Sergio Penco; Loredana Vesci; Rosanna Foderà; Fabiana Fosca Ferrara; Mario Berardino Guglielmi; Paolo Carminati; Sabrina Dallavalle; Gabriella Morini; Lucio Merlini; Augusto Orlandi; Franco Zunino
Differential antiproliferative mechanisms of novel derivative of benzimidazo[1,2-α]quinoline in colon cancer cells depending on their p53 status
Mirela Sedic; Miroslav Poznic; Peter Gehrig; Mike Scott; Ralph Schlapbach; Marijana Hranjec; Grace Karminski-Zamola; Kresimir Pavelic; Sandra Kraljevic Pavelic
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.